Department of Biochemistry, University of Ulsan College of Medicine, Seoul, Korea.
BMB Rep. 2010 Jun;43(6):413-8. doi: 10.5483/bmbrep.2010.43.6.413.
Beta-Amyloid (ABeta)-induced neuroinflammation is one of the key events in the development of neurodegenerative disease. We previously reported that KHG21834, a benzothiazole derivative, attenuates ABeta-induced degeneration of cortical and mesencephalic neurons in vitro. In the present work, we show that KHG21834 reduces ABeta-mediated neuroinflammation in brain. In vivo intracerebroventricular infusion of KHG21834 leads to decreases in the numbers of activated astrocytes and microglia and level of proinflammatory cytokines such as interleukin- 1Beta and tumor necrosis factor-alpha induced by ABeta in the hippocampus. This suppression of neuroinflammation is associated with decreased neuron loss, restoration of synaptic dysfunction biomarkers in the hippocampus to control level, and diminished amyloid deposition. These results may suggest the potential therapeutic efficacy of KHG21834 for the treatment of ABeta-mediated neuroinflammation.
β-淀粉样蛋白(Aβ)诱导的神经炎症是神经退行性疾病发展的关键事件之一。我们之前报道过,苯并噻唑衍生物 KHG21834 可减轻体外 Aβ诱导的皮质和中脑神经元变性。在本工作中,我们表明 KHG21834 可减轻 Aβ介导的脑内神经炎症。体内侧脑室注射 KHG21834 可减少 Aβ诱导的海马中活化星形胶质细胞和小胶质细胞的数量以及促炎细胞因子(如白细胞介素-1β和肿瘤坏死因子-α)的水平。这种神经炎症的抑制与神经元丢失的减少、海马中突触功能障碍生物标志物恢复到对照水平以及淀粉样蛋白沉积减少有关。这些结果可能表明 KHG21834 治疗 Aβ介导的神经炎症的潜在治疗效果。